Daiichi Sankyo Lifts FY2027 Guidance on Ordinary Income Recovery

Daiichi Sankyo Company, Limited (TSE:4568), Japan’s leading pharmaceutical manufacturer with core strengths in cardiovascular and infectious disease treatments, reported full-year results for fiscal 2026 (ended March 2026) showing robust operational growth offset by one-time charges that depressed bottom-line profitability. The company projects a significant rebound in ordinary income (keijo rieki, Japan’s recurring profit metric) for fiscal 2027, signaling confidence that current-period restructuring costs are temporary.

Key Financial Results — FY2026 (Full Year)

Business Overview

Daiichi Sankyo is a major domestic pharmaceutical player with established market positions in cardiovascular and infectious disease segments. The company is advancing its oncology pipeline through a strategic partnership with UK-based AstraZeneca, positioning itself for longer-term growth beyond its mature core franchises.

Analysis: Operational Strength Masked by One-Time Charges

The headline story of Daiichi Sankyo’s FY2026 results is a divergence between operating performance and reported profitability. Revenue growth of 12.6% (JPY 236.8bn increase) was accompanied by operating profit expansion of 15.1%, demonstrating operational leverage and pricing power. The 17.0% operating margin substantially exceeds typical pharmaceutical industry benchmarks, reflecting the company’s competitive positioning and product mix quality.

However, ordinary income declined 25.9% to JPY 263.4bn, a sharp contraction that appears disconnected from the operating profit story. This gap reflects approximately JPY 153.0bn in one-time charges—likely comprising asset write-downs, litigation settlements, or business restructuring costs—that flowed through non-operating items. Net profit fell 12.1% to JPY 259.9bn, indicating these charges cascaded to the bottom line after tax.

The divergence between operating profit growth and ordinary income decline is critical for international investors to understand. In Japan’s financial reporting framework, ordinary income includes non-operating income and expenses (interest, dividends, foreign exchange gains/losses) that do not exist in IFRS or US GAAP operating profit. This metric can obscure underlying business momentum, which is better captured by the 15.1% operating profit growth.

On the cost side, selling, general and administrative expenses rose 18.6%—outpacing revenue growth of 12.6%—suggesting elevated spending on new product launches and market expansion. Research and development investment increased 6.8%, consistent with the company’s commitment to pipeline advancement, particularly in oncology.

Operating cash flow improved to JPY 77.7bn from JPY 53.8bn in the prior year, though investment activities consumed JPY 148.2bn, indicating active capital deployment for M&A and facility expansion.

Next Year Guidance

Management’s FY2027 guidance reflects a conservative stance on operating profit (flat vs. FY2026) while projecting a substantial 24.9% recovery in ordinary income. This asymmetry indicates management expects the one-time charges of FY2026 to largely dissipate, restoring ordinary income to normalized levels. Revenue growth is forecast to moderate to 7.4% from the current 12.6%, suggesting some normalization after the current period’s elevated growth. The operating profit guidance of JPY 360.0bn—unchanged from FY2026—implies that continued SG&A and R&D investment will offset incremental revenue gains, a cautious view that may reflect uncertainty around new product ramp timing or competitive pressures.

What to Watch

Pipeline execution and oncology partnership: The AstraZeneca collaboration is central to Daiichi Sankyo’s medium-term growth narrative. Clinical trial outcomes and regulatory approvals for co-developed oncology assets will be critical catalysts. Any delays or setbacks could pressure the company’s ability to sustain revenue growth beyond the current 7–12% range.

Cost structure normalization: SG&A expenses rising faster than revenue is unsustainable. Management must demonstrate that current spending supports future revenue expansion; otherwise, operating margin compression could persist despite flat operating profit guidance.

Dividend sustainability: The company increased its dividend 30% in FY2026 (to JPY 78/share) and projects a further increase to JPY 100/share for FY2027, despite net profit declining 12.1%. This aggressive capital return policy signals confidence in cash generation but warrants monitoring against free cash flow trends, particularly given elevated capital expenditure.

Source: Original filing (TDnet) | 日本語版

This article is for informational purposes only and does not constitute investment advice. Financial figures are AI-extracted and may contain errors — always verify against the original filing.